No Data
What is the impact on the domestic Pharmaceutical industry? Many listed companies respond to the USA's tariff on Pharmaceutical.
① Most surveyed listed Pharmaceutical companies are not panicking. Some companies state that if Pharmaceutical tariffs are implemented, they will raise prices to ensure product gross margin; ② Other companies mention that their products are difficult to substitute in the U.S. and are closely monitoring related developments; ③ Industry experts state that if Pharmaceutical tariffs are implemented, compared to Active Pharmaceutical Ingredients and generic drugs, Innovative Drugs may be the least impacted.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Shineway Pharmaceutical's 2024 Profit Slides 13%; Shares Fall 8%
Hong Kong stocks moving | SHINEWAY PHARM (02877) fell over 7% in the afternoon, with last year's revenue and net profit both showing double-digit declines.
SHINEWAY PHARM (02877) fell over 7% in the afternoon, as of the time of writing, down 7.63%, reported at HKD 8.11, with a transaction volume of HKD 15.5962 million.
SHINEWAY PHARM announced its annual performance, with a profit of 0.84 billion yuan for the year, a year-on-year decrease of 13.35%.
SHINEWAY PHARM (02877) announced its annual performance for 2024, with an operating revenue of 3.778 billion yuan (RMB, the same below), a year-on-year decrease of 16.35%; annual profit of 0.84 billion yuan, a year-on-year decrease of 13.35%; basic earnings per share of 111 cents; a proposed first interim dividend of 36 cents per share. The announcement stated that in 2024, the group's overall operating revenue significantly decreased, mainly due to the high baseline effect from the previous year's surge in demand for respiratory, cold, and anti-infection pharmaceuticals, along with multiple factors such as changes in market demand due to the macro economy and policy adjustments, leading to a decline in overall sales.
China Shineway Pharmaceutical Group Limited's (HKG:2877) 30% Share Price Surge Not Quite Adding Up
